Clinical trials for Cell body

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44341 clinical trials with a EudraCT protocol, of which 7370 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

1,412 result(s) found for: Cell body. Displaying page 71 of 71.

EudraCT Number: 2020-005101-12

Sponsor Protocol Number: AGO-OVAR27

Start Date*: 2021-11-09

Sponsor Name:AGO Research GmbH

Full Title: Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery ...

Medical condition: Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment planning.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10057529	Ovarian cancer metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070906	Ovarian cancer stage II	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070907	Ovarian cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10070908	Ovarian cancer stage IV	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016182	Fallopian tube cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016185	Fallopian tube cancer stage II	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016186	Fallopian tube cancer stage III	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016187	Fallopian tube cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2011-002528-42

Sponsor Protocol Number: 0431-083

Start Date*: 2011-12-30

Sponsor Name:Merck Sharp & Dohme Corp. A subsidiary of Merck & Co. Inc

Full Title: A Phase III, Multicenter, Double-Blind, Randomized, Placebo- and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Me...

Medical condition: Type 2 Diabetes Mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004861	10045242	Type II diabetes mellitus	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: LV (Completed) LT (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed) BG (Completed) AT (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) SK (Completed) Outside EU/EEA GR (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2010-021491-28

Sponsor Protocol Number: V419-008

Start Date*: 2012-01-26

Sponsor Name:Sanofi Pasteur MSD S.N.C.

Full Title: A phase III randomized, double-blind, active-comparator controlled clinical trial to study the safety, tolerability, and immunogenicity of V419 in healthy infants when given at 2, 4, and 11 to 12 m...

Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza type...

Disease:	Version	SOC Term	Classification Code	Term	Level
	16.0	100000004848	10019743	Hepatitis B virus (HBV)	LLT
	16.0	100000004865	10069543	Hemophilus influenzae type b immunization	LLT
	16.0	100000004865	10069593	Pertussis immunization	LLT
	16.0	100000004865	10054181	Hepatitis B immunization	LLT
	16.0	100000004865	10053386	Poliomyelitis vaccine	LLT
	16.0	100000004865	10054180	Diphtheria immunization	LLT
	16.0	100000004865	10054183	Tetanus immunization	LLT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: FI (Completed) SE (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2017-000091-28

Sponsor Protocol Number: EFC15081

Start Date*: 2017-09-04

Sponsor Name:Sanofi-aventis recherche & développement

Full Title: Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extensio...

Medical condition: Type 1 diabetes mellitus Type 2 diabetes mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10027433 - Metabolism and nutrition disorders	10067585	Type 2 diabetes mellitus	PT
	20.0	10027433 - Metabolism and nutrition disorders	10067584	Type 1 diabetes mellitus	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) FI (Completed) DE (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2010-021490-37

Sponsor Protocol Number: V419-007

Start Date*: 2011-03-09

Sponsor Name:Sanofi Pasteur MSD

Full Title: A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4, and 12 Months.

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10042613 - Surgical and medical procedures	10054130	Hepatitis B immunisation	PT
	14.1	10042613 - Surgical and medical procedures	10054129	Diphtheria immunisation	PT
	14.1	10042613 - Surgical and medical procedures	10053386	Poliomyelitis vaccine	LLT
	14.1	10042613 - Surgical and medical procedures	10069543	Hemophilus influenzae type b immunization	LLT
	14.1	10042613 - Surgical and medical procedures	10069577	Pertussis immunisation	PT
	14.1	10021881 - Infections and infestations	10019731	Hepatitis B	PT
	14.1	10042613 - Surgical and medical procedures	10054131	Tetanus immunisation	PT

Population Age: Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: BE (Completed) FI (Completed) DE (Completed)

Trial results: View results

EudraCT Number: 2018-004142-42

Sponsor Protocol Number: IM011073

Start Date*: Information not available in EudraCT

Sponsor Name:Bristol-Myers Squibb International Corporation

Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis

Medical condition: Lupus Nephritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10038359 - Renal and urinary disorders	10025140	Lupus nephritis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) BE (Completed) NL (Completed) CZ (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)

Trial results: View results

EudraCT Number: 2016-002817-22

Sponsor Protocol Number: AAG-G-H-1624

Start Date*: 2017-02-09

Sponsor Name:TETEC Tissue Engineering Technologies - AG

Full Title: Prospective, Multicenter, Single-arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of NOVOCART® Inject plus in the Treatment of Cartilage Defects of the Knee

Medical condition: Repair of cartilage defects of the knee (medial or lateral femoral condyle or tibial plateau, trochlea or patella) caused by traumatic events or osteochondritis dissecans (defect size is ≥ 4 and ≤...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000009764	10007702	Cartilage biopsy	LLT
	20.0	10042613 - Surgical and medical procedures	10052913	Cartilage operation	PT
	20.0	100000019132	10007705	Cartilage damage	LLT
	20.0	100000022571	10057104	Cartilage repair	LLT
	20.0	10042613 - Surgical and medical procedures	10064112	Cartilage graft	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) CZ (Completed) DE (Completed) PL (Completed) LT (Completed)

Trial results: View results

EudraCT Number: 2019-003265-17

Sponsor Protocol Number: S63466

Start Date*: 2020-09-10

Sponsor Name:Universitair Ziekenhuis Leuven (UZ Leuven)

Full Title: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)

Medical condition: Type 1 diabetes mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	10027433 - Metabolism and nutrition disorders	10067584	Type 1 diabetes mellitus	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: BE (Completed) DE (Completed) FI (Completed) SI (Completed) AT (Completed) IT (Completed) DK (Completed)

Trial results: (No results available)

EudraCT Number: 2008-000252-28

Sponsor Protocol Number: SHCVOLT1

Start Date*: 2009-03-13

Sponsor Name:Cambridge University Hospitals NHS Foundation Trust

Full Title: A Multi-Centre Prospective Controlled Trial Comparing Calcineurin Inhibitor Monotherapy With Sirolimus Monotherapy in Hepatitis C Infected Patients with Hepatic Fibrosis Following Liver Transplanta...

Medical condition: Patients who have undergone liver transplantation and are infected with Hepatitis C virus.

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10052779	Transplant rejections	HLT
	9.1		10024970	Respiratory tract infections	HLGT
	9.1		10046577	Urinary tract infections	HLT
	9.1		10001032	Acute pyelonephritis	LLT
	9.1		10040072	Septicaemia	LLT
	9.1		10019972	Herpes viral infections	HLT
	9.1		10028440	Mycobacterial infectious disorders	HLGT
	9.1		10015107	Epstein-Barr viral infections	HLT
	9.1		10011831	Cytomegalovirus infection	LLT
	9.1		10019974	Herpes zoster	LLT
	9.1		10058872	Fungal sepsis	LLT
	9.1		10040808	Skin cancer	PT
	9.1		10051358	Post transplant lymphoproliferative disorder	LLT
	9.1		10043555	Thrombocytopenias	HLT
	9.1		10037561	Purpura thrombocytopenic	LLT
	9.1		10002034	Anaemia	PT
	9.1		10018932	Haemolytic uraemic syndrome	PT
	9.1		10024384	Leukopenia	PT
	9.1		10029355	Neutropenias	HLT
	9.1		10033661	Pancytopenia	PT
	9.1		10013505	Disturbance of liver function tests	LLT
	9.1		10002218	Anaphylaxis	LLT
	9.1		10002425	Angioedemas	HLT
	9.1		10015665	Exfoliative dermatitis	LLT
	9.1		10020764	Hypersensitivity vasculitis	LLT
	9.1		10021015	Hypokalaemia	PT
	9.1		10021058	Hypophosphataemia	PT
	9.1		10020603	Hypercholesterolaemia	PT
	9.1		10020635	Hyperglycaemia	PT
	9.1		10020869	Hypertriglyceridaemia	PT
	9.1		10043071	Tachycardia	PT
	9.1		10034474	Pericardial effusion	PT
	9.1		10048642	Lymphocele	PT
	9.1		10051055	Deep vein thrombosis	PT
	9.1		10037377	Pulmonary embolism	PT
	9.1		10025282	Lymphoedema	PT
	9.1		10035742	Pneumonitis	PT
	9.1		10035598	Pleural effusion	PT
	9.1		10015090	Epistaxis	PT
	9.1		10037394	Pulmonary haemorrhage	PT
	9.1		10000081	Abdominal pain	PT
	9.1		10012735	Diarrhoea	PT
	9.1		10042128	Stomatitis	PT
	9.1		10033645	Pancreatitis	PT
	9.1		10000496	Acne	PT
	9.1		10037844	Rash	PT
	9.1		10003239	Arthralgia	PT
	9.1		10031264	Osteonecrosis	PT
	9.1		10037032	Proteinuria	PT
	9.1		10029164	Nephrotic syndrome	PT
	9.1		10030124	Oedema peripheral	PT
	9.1		10021519	Impaired healing	PT
	9.1		10030095	Oedema	PT
	9.1		10037660	Pyrexia	PT
	9.1		10005630	Blood lactate dehydrogenase increased	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2007-005434-37

Sponsor Protocol Number: IM101-174

Start Date*: 2008-07-24

Sponsor Name:Bristol Myers Squibb International Corporation

Full Title: A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects with Rheumatoid Arth...

Medical condition: RHEUMATOID ARTHRITIS, NOS

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10039073	Rheumatoid arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) IE (Completed) HU (Completed) GB (Completed) BE (Completed) DE (Completed) NL (Completed) IT (Completed) AT (Prematurely Ended) GR (Completed)

Trial results: View results

EudraCT Number: 2007-002522-29	Sponsor Protocol Number: 352.2046	Start Date*: 2008-10-08
Sponsor Name:Boehringer Ingelheim España, S.A.
Full Title: A randomised, double-blind, active-controlled study to evaluate the impact of stepwise withdrawal of inhaled corticosteroid treatment in patients with severe to very severe chronic obstructive pulm...
Medical condition: Chronic obstructive pulmonary disease (COPD). Enfermedad Pulmonar Obstructiva Crónica.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: ES (Completed) FR (Completed) BE (Completed) DE (Completed) GB (Completed) DK (Completed) NL (Completed) HU (Completed) IT (Completed) GR (Completed) BG (Completed)
Trial results: View results

EudraCT Number: 2011-005798-22

Sponsor Protocol Number: AAG-G-H-1202

Start Date*: 2012-11-05

Sponsor Name:TETEC – Tissue Engineering Technologies – AG

Full Title: A Clinical Study to Evaluate the Safety and Effectiveness of NOVOCART® 3D plus Compared to Microfracture in the Treatment of Articular Cartilage Defects of the Knee.

Medical condition: Repair of localized, full-thickness cartilage defects of the femoral condyle (medial, lateral or trochlea) of 2-6cm².

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10042613 - Surgical and medical procedures	10052913	Cartilage operation	PT
	20.0	100000004863	10007705	Cartilage damage	LLT
	20.0	10042613 - Surgical and medical procedures	10057104	Cartilage repair	LLT
	20.0	10042613 - Surgical and medical procedures	10064112	Cartilage graft	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) HU (Completed) LV (Completed) LT (Completed) FR (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Wed Jun 11 03:50:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA